X
[{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iNtRON Confirms Efficacy of CDL200 Against CDI Clinical Isolates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"U.S. Army DEVCOM","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iNtRON Signs Bacteriophage Development Project with U.S. Army DEVCOM","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"$CHECK CHECK","upfrontCash":"Undisclosed","newsHeadline":"Basilea Announces Exclusive License and Option Agreement for Potential First-In-Class Clinical-Stage Antibacterial Agent","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iNtRON, Executes Evaluation License and Option Agreement for SAL200","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Basilea Announces Exclusive License and Option Agreement for Potential First-in-class Clinical-Stage Antibacterial Agent","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iNtRON, Development of PHAGERIA\u00ae Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by iNtRON Biotechnology
Filters
Companies By Therapeutic Area
Details:
P18-BE3CRC is a drug candidate developed using the Phageria platform technology for bacteriophage-based drugs. It is being evaluated in preclinical trials for the treatment of colorectal cancer.
Lead Product(s):
P18-BE3CRC
Therapeutic Area: Oncology
Product Name: P18-BE3CRC
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 14, 2024
Details:
Upon successful completion of the preclinical evaluation phase, Basilea will have the exclusive option to license LSVT-1701 (tonabacase) for further clinical development and commercialization.
Lead Product(s):
Tonabacase
Therapeutic Area: Infections and Infectious Diseases
Product Name: LSVT-1701
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Basilea Pharmaceutica
Deal Size: $CHECK CHECK
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
October 31, 2023
Details:
Under the agreement, Basilea will investigate SAL200 (tonabacase), a potential first-in-class clinical-stage antibacterial of the endolysin class, against methicillin-resistant and methicillin-susceptible Staphylococcus aureus.
Lead Product(s):
Tonabacase
Therapeutic Area: Infections and Infectious Diseases
Product Name: SAL200
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Basilea Pharmaceutica
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
October 31, 2023
Details:
Under the agreement, iNtRON grants Basilea exclusive right for preclinical evaluation of the antibacterial bio-drug N-Rephasin SAL200 (tonabacase), a novel endolysin-based anti-staphylococcal drug formulated for injection.
Lead Product(s):
Tonabacase
Therapeutic Area: Infections and Infectious Diseases
Product Name: N-Rephasin SAL200
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Basilea Pharmaceutica
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
October 30, 2023
Details:
The agreement aims to develop bacteriophages targeting strains causing urinary tract infections for combating Uropathogenic Escherichia coli (UPEC) infections.
Lead Product(s):
Undisclosed
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Large molecule
Partner/Sponsor/Collaborator:
U.S. Army DEVCOM
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
September 03, 2023
Details:
CDL200 is a novel endolysin-based anti- Clostridioides difficile causes an infection of colon, showed potent and rapid activity against 100% clinical isolates from multi-nation and has no disturbance of normal flora in human's gut.
Lead Product(s):
CDL200
Therapeutic Area: Infections and Infectious Diseases
Product Name: CDL200
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 11, 2022